Earticle

현재 위치 Home

Original Article

Colistimethate 분무요법 시행 환자에서 투여 전후 신기능의 변화
Changes in Renal Function by Nebulized Colistimethate Treatment

첫 페이지 보기
  • 발행기관
    한국임상약학회 바로가기
  • 간행물
    한국임상약학회지 KCI 등재 바로가기
  • 통권
    제27권 제2호 (2017.06)바로가기
  • 페이지
    pp.92-98
  • 저자
    안혜진, 정유진, 김재송, 김수현, 손은선
  • 언어
    한국어(KOR)
  • URL
    https://www.earticle.net/Article/A311813

※ 기관로그인 시 무료 이용이 가능합니다.

4,000원

원문정보

초록

영어
Background: Nebulized colistimethate is increasingly used, because there are problems such as renal dysfunction and low distribution within the lungs when colistimethate is administered intravenously. This study was designed to compare and analyze the changes in renal function by of nebulized colistimethate treatment for its safe administration. Methods: This study retrospectively reviewed the electronic medical records of adult patients above 19 years old, receiving only the nebulized colistimethate at least 4 days in Yonsei university health system from Nov 2014 to Aug 2015. Acute kidney injury (AKI) was determined by using the RIFLE criteria (Risk, Injury, Failure, Loss and End-stage renal disease) according to serum creatinine (SCr) levels before and after use of nebulized colistimethate. Results: 48 patients were included our study and their SCr increased significantly after nebulized colistimethate treatment (SCr0 vs. SCr1; 0.85±0.80 vs. 1.00±0.82 mg/dL, n=48, p<0.001), but the changes were in normal range according to the standards at Yonsei university health systema. Among 48 patients, 38 patients were in the non-AKI group (79.2%), and 10 patients developed AKI (20.8%). Within the AKI group, 2 patients were in the Injury group (20%) and the other 8 in the Risk group (80%). Conclusion: There was no significant difference in age, dosage and duration of treatment between AKI group and non-AKI group (p>0.05). The study has a significance in that it reviewed the safety of nebulized colistimethate only treatment to national patients, analyzing its nephrotoxicity. It has confirmed that nebulized colistimethate is a safer method than intravenous injection, and requires to establish a guideline for the use of nebulized colistimethate in further studies with broader patient groups. a: SCr Male 0.68-1.19 mg/dL, Female 0.49-0.91 mg/dL

목차

ABSTRACT
 연구 방법
  대상 환자
 연구 결과
  대상 환자의 특성
  치료 후 SCr의 변화와 그에 때른 급성 신손상 발생률
  치료 후 BUN, CrCl의 변화
  치료 후 균의 음전률
  각 군의 비교
 고찰
 결론
 참고문헌

키워드

Nebulized colistimethate treatment serum creatinine renal function multidrug- resistant gram-negative bacteria

저자

  • 안혜진 [ Hye Jin Ahn | 세브란스병원 약무국 ]
  • 정유진 [ Yoo Jin Jung | 세브란스병원 약무국 ]
  • 김재송 [ Jae Song Kim | 세브란스병원 약무국 ]
  • 김수현 [ Soo Hyun Kim | 세브란스병원 약무국 ]
  • 손은선 [ Eun Sun Son | 세브란스병원 약무국 ] Corresponding author

참고문헌

자료제공 : 네이버학술정보

간행물 정보

발행기관

  • 발행기관명
    한국임상약학회 [Korean College of Clinical Pharmacy]
  • 설립연도
    1
  • 분야
    의약학>약학
  • 소개
    합리적 약물치료(rational pharmacotherapy)의 보장 및 증진을 궁극목적으로 하며 이를 달성하기 위해 임상약학의 발전과 회원 상호간의 친목을 도모한다.

간행물

  • 간행물명
    한국임상약학회지 [Korean Journal of Clinical Pharmacy]
  • 간기
    계간
  • pISSN
    1226-6051
  • 수록기간
    1991~2026
  • 등재여부
    KCI 등재
  • 십진분류
    KDC 518 DDC 615

이 권호 내 다른 논문 / 한국임상약학회지 제27권 제2호

    피인용수 : 0건 (자료제공 : 네이버학술정보)

    함께 이용한 논문 이 논문을 다운로드한 분들이 이용한 다른 논문입니다.

      출처 : 네이버학술정보

        0개의 논문이 장바구니에 담겼습니다.

        페이지 저장
        소속기관 조회
        이용자님의 소속기관(단체)이 서비스에 가입되어 있는지 확인해 보십시오.
        기관회원에 소속되어 있는 이용자는 원문을 무료로 이용할 수 있습니다.